Decoding the Nuances of Diagnosis and Emerging Therapeutic Options in HCC
March 31, 2023
March 31, 2024
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the American Liver Foundation (ALF).
This activity is supported by an educational grant from AstraZeneca and Eisai, Inc.
- Physicians — 1.0 AMA PRA Category 1 Credit™
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The primary target audiences for the HCP activity are medical oncologists, GI oncologists, hepatologists, gastroenterologists, radiation oncologists, surgical oncologists, oncology nurses and nurse navigators, nurse practitioners, physician assistants, and other professionals involved in the care of patients with HCC.
Hepatocellular carcinoma (HCC) is a heterogeneous, difficult-to-treat cancer for which chemotherapy has only limited efficacy. In addition to early diagnosis, effective therapies are needed to improve outcomes in patients with HCC for whom surgical intervention is inadequate. New and emerging treatment strategies with immunotherapies and kinase inhibitors are providing clinicians with an expanded treatment arsenal with which to treat these patients.
Join Dr. Ghassan Abou-Alfa and Dr. Amit Singal to discuss the optimization of diagnostic and treatment strategies for patients with HCC. Panelists will explore the current standard of care, where newly approved options fit, as well as the latest clinical data on the efficacy and safety of new and emerging options. Experts will also share strategies to overcome the stigma faced by patients with HCC and barriers to care, and how to encourage patients to participate in treatment decision-making and access clinical trials for which they may be eligible.
Upon completion of this activity, participants should be better able to:
- Apply guideline-based strategies to improve timely diagnosis, including adequate surveillance of patients at high risk of developing HCC
- Evaluate new and emerging approaches for adjuvant, locoregional, and first-line treatment for patients with HCC
- Review strategies to individualize treatment plans that include multidisciplinary and patient perspectives
Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
Amit Singal, MD, MS
Professor of Medicine
Chief of Hepatology
Medical Director, Liver Tumor Program
UT Southwestern Medical Center
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 ACCME Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
- Ghassan Abou-Alfa, MD, MBA
- Consulting Fee: Astra Zeneca, Autem, Boehringer Ingelheim, Eisai, Exelixis, Genentech/Roche, Helio, Incyte, Ipsen, Merck, Newbridge, Novartis, QED, Servier, Yiviva
- Contracted Research: Arcus, AstraZeneca, BioNTech, BMS, Celgene, Genentech/Roche, Helsinn, Puma, QED, Yiviva
- Amit Singal, MD, MS
- Consulting Fee: FujiFilm Medical Sciences, Exact Sciences, Roche, Glycotest, GRAIL, Freenome, Universal Dx, Genentech, AstraZeneca, Eisai, Bayer, Exelixis, TARGET RWE.
The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.
Instructions for Participation and Credit
Estimated Time to Complete
This activity should take approximately 60 minutes to complete.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive ACCME Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com..
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor do we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting support@PlatformQHealth.com with the subject line “Data Request”